PASG has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PASG has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Passage Bio's share price for the quarter that ended in Dec. 2024 was $0.5671. Passage Bio's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 62.06 Mil. Therefore, Passage Bio's market cap for the quarter that ended in Dec. 2024 was $35.20 Mil.
Passage Bio's quarterly market cap declined from Jun. 2024 ($49.05 Mil) to Sep. 2024 ($43.24 Mil) and declined from Sep. 2024 ($43.24 Mil) to Dec. 2024 ($35.20 Mil).
Passage Bio's annual market cap declined from Dec. 2022 ($75.37 Mil) to Dec. 2023 ($55.49 Mil) and declined from Dec. 2023 ($55.49 Mil) to Dec. 2024 ($35.20 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Passage Bio's Enterprise Value for Today is $-27.23 Mil.
The historical data trend for Passage Bio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Passage Bio Annual Data | ||||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Market Cap | Get a 7-Day Free Trial | 1,166.38 | 344.46 | 75.37 | 55.49 | 35.20 |
Passage Bio Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Market Cap | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
55.49 | 83.18 | 49.05 | 43.24 | 35.20 |
For the Biotechnology subindustry, Passage Bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Passage Bio's Market Cap distribution charts can be found below:
* The bar in red indicates where Passage Bio's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Passage Bio's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
Market Cap (A: Dec. 2024 ) | = | Share Price (A: Dec. 2024 ) | * | Shares Outstanding (EOP) (A: Dec. 2024 ) |
= | $0.5671 | * | 62.062 | |
= | $35.20 |
Passage Bio's Market Cap for the quarter that ended in Dec. 2024 is calculated as
Market Cap (Q: Dec. 2024 ) | = | Share Price (Q: Dec. 2024 ) | * | Shares Outstanding (EOP) (Q: Dec. 2024 ) |
= | $0.5671 | * | 62.062 | |
= | $35.20 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Passage Bio (NAS:PASG) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of Passage Bio's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Kathleen Borthwick | officer: SVP, Interim CFO | C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103 |
Orbimed Advisors Llc | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Mark S Forman | officer: Chief Medical Officer | C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103 |
Simona King | officer: Chief Financial Officer | C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103 |
Dolan Sondhi | director | C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103 |
Alexandros Fotopoulos | officer: Chief Technical Officer | TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103 |
Sandip Kapadia | director | 450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011 |
William Chou | director, officer: Chief Executive Officer | C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103 |
Monika Maria Toernsen | officer: Chief Commercial Officer | ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103 |
Michael E. Kamarck | director | C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406 |
Bruce A Goldsmith | director, officer: CEO and President | C/O PASSAGE BIO, INC., TWO COMMERCE SQ, 2001 MARKET ST, 28TH FL, PHILADELPHIA PA 19103 |
Orbimed Capital Gp Vii Llc | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Brian Burkavage | officer: Controller | C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103 |
Derrell Porter | director | C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD. #900, SOUTH SAN FRANCISCO CA 94080 |
Richard Steven Morris | officer: Chief Financial Officer | 397 EAGLEVIEW BOULEVARD, EXTON PA 19341 |
From GuruFocus
By GuruFocus News • 12-12-2024
By GuruFocus News • 01-09-2025
By GuruFocus Research • 02-08-2024
By Marketwired • 06-05-2024
By Marketwired • 09-23-2024
By GuruFocus News • 12-27-2024
By Marketwired • 11-13-2024
By GuruFocus News • 01-04-2025
By GuruFocus News • 11-14-2024
By Marketwired • 08-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.